Abstract
Conjugates of gold nanoparticles with two isolated tularemia microbe antigens, a protective antigen complex and a glycosylated protein complex, are used to obtain anti-tularemia sera and to vaccinate animals. A conjugate of gold nanoparticles with the glycosylated protein complex during the subcutaneous immunization of mice is more effective than the unconjugated antigen, which is evident from the increase in protectiveness and antibody titers. The use of conjugates of both antigens with gold nanoparticles during the immunization of rabbits makes it possible to obtain sera with a high titer of specific antibodies (1/64–1/128 titer in the diffusion precipitation reaction and 1/5120–1/10240 in the reaction of indirect hemagglutination) during a relatively short period of time and with minimal antigen consumption (1.8–10 mg). The use of immunoglobulins extracted from sera during the enzyme-linked immunosorbent assay makes it possible to detect Francisella tularensis cells of different subspecies in the amount of (5.2 ± 0.5) × 105 MC/mL with 100% specificity for heterologous strains at a concentration of 108 MC/mL, which enables their subsequent application in the production of preparations for the diagnostics of tularemia.
Article PDF
Similar content being viewed by others
References
M. Maurin and M. Gyuranecz, “Tularaemia: clinical aspects in europe,” Lancet Infect. Dis. 16, 113–124 (2016).
T. Y. Kudryavtseva, D. V. Trankvilevsky, A. N. Mokrievich, V. P. Popov, N. S. Morozova, M. V. Zarochentsev, A. V. Mazepa, L. P. Okunev, A. V. Kholin, S. A. Kosilko, Y. M. Fedorov, M. V. Khramov, and I. A. Dyatlov, “Epizootic and epidemic situation on tularemia in the russian federation in 2015 and prognosis for 2016,” Probl. Osobo Opasn. Infekts., No. 1, 28–32 (2016).
D. Putzova, I. Senitkova, and J. Stulik, “Tularemia vaccines,” Folia Microbiol. 61, 495–504 (2016).
R. Sunagar, S. Kumar, B. J. Franz, and E. J. Gosselin, “Tularemia vaccine development: paralysis or progress?,” Vaccine (Auckl.) 2016 (6), 9–23 (2016).
M. J. Hepburn and A. J. Simpson, “Tularemia: current diagnosis and treatment options,” Expert Rev. Anti Infect. Ther. 6, 231–240 (2008).
G. G. Onishchenko and V. V. Kutyrev, Laboratory Diagnosis of Dangerous Infectious Diseases: A Practical Guide (Shiko, Moscow, 2013) [in Russian].
E. M. Kuznetsova, O. A. Volokh, E. A. Smol’kova, T. N. Shchukovskaya, I. A. Shepelev, N. G. Avdeeva, A. L. Kravtsov, and A. K. Nikiforov, “Immunobiological properties of francisella tularensis antigen complexes,” Probl. Osobo Opasn. Infekts., No. 3, 46–49 (2011).
H. M. Rowe and J. F. Huntley, “The francisella tularensis envelope and virulence,” Front. Cell. Infect. Microbiol. 5, 94 (2015).
M. Zaman, M. F. Good, and I. Toth, “Nanovaccines and their mode of action,” Methods 60, 226–231 (2013).
C. K. Prashant, M. Kumar, and A. K. Dinda, “Nanoparticle based tailoring of adjuvant function: the role in vaccine development,” J. Biomed. Nanotechnol. 10, 2317–2331 (2014).
A. N. Ilinskaya and M. A. Dobrovolskaia, “Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future,” Toxicol. Appl. Pharmacol. 299, 70–77 (2016).
L. M. Marques Neto, A. Kipnis, and A. P. Junqueira-Kipnis, “Role of metallic nanoparticles in vaccinology: implications for infectious disease vaccine development,” Front. Immunol. 8, 239 (2017).
L. A. Dykman, M. V. Sumaroka, S. A. Staroverov, I. S. Zaitseva, and V. A. Bogatyrev, “Immunogenic properties of colloidal gold,” Biol. Bull. Russ. Acad. Sci. 31, 75–79 (2004).
J. A. Salazar-González, O. González-Ortega, and S. Rosales-Mendoza, “Gold nanoparticles and vaccine development,” Expert Rev. Vaccines 14, 1197–1211 (2015).
L. A. Dykman, S. A. Staroverov, V. A. Bogatyrev, and S. Y. Shchyogolev, “Adjuvant properties of gold nanoparticles,” Nanotechnol. Russ. 5, 748–761 (2010).
L. A. Dykman and N. G. Khlebtsov, “Immunological properties of gold nanoparticles,” Chem. Sci. 8, 1719–1735 (2017).
E. M. Kuznetsova, O. A. Volokh, I. A. Shepelev, and A. K. Nikiforov, “The components of francisella tularensis protective antigene complex,” Mol. Genet., Mikrobiol. Virusol., No. 3, 22–25 (2012).
E. M. Kuznetsova, O. A. Volokh, I. A. Shepelev, and N. G. Avdeeva, “Glycosylated protein complex francisella tularensis,” in Innovative Technologies in Anti-Epidemic Protection of the Population, Ed. by E. I. Efimov (Areal, Nizh. Novgorod, 2011), pp. 93–95 [in Russian].
G. Frens, “Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions,” Nat. Phys. Sci. 241 (105), 20–22 (1973).
W. Geoghegan and G. Ackerman, “Adsorption of horseradish peroxidase, ovomucoid and anti-immunoglobulin to colloidal gold for the indirect detection od concanavalin a, wheat germ agglutinin and goat antihuman immunoglobuli G on cell surfaces at the electron microscopic level: a new method, theory and application,” J. Histochem. Cytochem. 25, 1187–1200 (1977).
A. I. Karpishchenko, Medical Laboratory Technologies: A Guide to Clinical Laboratory Diagnostics (GOETARMedia, Moscow, 2012) [in Russian].
S. Glants, Biomedical Statistics (Praktika, Moscow, 1998) [in Russian].
V. S. Khlebnikov, I. R. Golovlev, D. P. Kulevatskii, S. F. Averin, S. Yu. Pshirkov, N. V. Tokhtamysheva, V. E. Zhemchugov, L. A. Safonova, V. N. Gerasimov, A. M. Chugunov, S. S. Vetchinin, V. G. Galaktionov, and S. S. Afanas’ev, “Biochemical, antigenic and protective properties of the outer membrane of tularemia pathogens,” Mol. Genet., Mikrobiol. Virusol., No. 7, 15–20 (1991).
L. A. Dykman, S. A. Staroverov, A. S. Fomin, V. A. Khanadeev, B. N. Khlebtsov, and V. A. Bogatyrev, “Gold nanoparticles as an adjuvant: influence of size, shape, and technique of combination with CpG on antibody production,” Int. Immunopharmacol. 54, 163–168 (2018).
A. N. Somov, T. B. Kravchenko, V. M. Pavlov, G. M. Vakhrameeva, T. I. Kombarova, R. I. Mironova, V. V. Firstova, O. V. Kalmantaeva, S. S. Vetchinin, and A. N. Mokrievich, “Antigenic and immunogenic characteristics of dissolved, adsorbed and microencapsulated formulations of acid-insoluble complex from Francisella tularensis 15 NIIG strain,” Biotekhnologiya 33 (5), 23–34 (2017).
S. Chattopadhyay, J.-Y. Chen, H.-W. Chen, and C.-M. J. Hu, “Nanoparticle vaccines adopting viruslike features for enhanced immune potentiation,” Nanotheranostics 1, 244–260 (2017).
S. A. C. Carabineiro, “Applications of gold nanoparticles in nanomedicine: recent advances in vaccines,” Molecules 22, 857 (2017).
Y. Shen, T. Hao, S. Ou, C. Hu, and L. Chen, “Applications and perspectives of nanomaterials in novel vaccine development,” Med. Chem. Commun. 9, 226–238 (2018).
L. C.-W. Lin, S. Chattopadhyay, J. C. Lin, C. M. J. Hu, “Advances and opportunities in nanoparticle-and nanomaterials-based vaccines against bacterial infections,” Adv. Healthcare Mater. 7, e1701395 (2018).
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © L.A. Dykman, O.A. Volokh, E.M. Kuznetsova, A.K. Nikiforov, 2018, published in Rossiiskie Nanotekhnologii, 2018, Vol. 13, Nos. 7–8.
Rights and permissions
About this article
Cite this article
Dykman, L.A., Volokh, O.A., Kuznetsova, E.M. et al. Immunogenicity of Conjugates of Protective Antigen Complexes of Tularemia Microbe with Gold Nanoparticles. Nanotechnol Russia 13, 384–392 (2018). https://doi.org/10.1134/S1995078018040055
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1995078018040055